Lantheus

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Lantheus and other ETFs, options, and stocks.

About LNTH

Lantheus Holdings, Inc. engages in the provision of diagnostic imaging and nuclear medicine products. The firm develops products that help healthcare professionals in patient management and outcomes and assists clinicians with the detection of cardiovascular disease. 

CEO
Brian A. Markison
CEOBrian A. Markison
Employees
808
Employees808
Headquarters
Bedford, Massachusetts
HeadquartersBedford, Massachusetts
Founded
1956
Founded1956
Employees
808
Employees808

LNTH Key Statistics

Market cap
4.10B
Market cap4.10B
Price-Earnings ratio
25.10
Price-Earnings ratio25.10
Dividend yield
Dividend yield
Average volume
990.61K
Average volume990.61K
High today
$62.60
High today$62.60
Low today
$59.35
Low today$59.35
Open price
$59.83
Open price$59.83
Volume
1.29M
Volume1.29M
52 Week high
$111.29
52 Week high$111.29
52 Week low
$47.25
52 Week low$47.25

Stock Snapshot

The current Lantheus(LNTH) stock price is $61.87, with a market capitalization of 4.1B. The stock trades at a price-to-earnings (P/E) ratio of 25.10.

During the trading session on 2025-12-04, Lantheus(LNTH) shares reached a daily high of $62.60 and a low of $59.35. At a current price of $61.87, the stock is +4.2% higher than the low and still -1.2% under the high.

Trading volume for Lantheus(LNTH) stock has reached 1.29M, versus its average volume of 990.61K.

Over the past 52 weeks, Lantheus(LNTH) stock has traded between a high of $111.29 and a low of $47.25.

Over the past 52 weeks, Lantheus(LNTH) stock has traded between a high of $111.29 and a low of $47.25.

LNTH News

Simply Wall St 6d
Lantheus Holdings To Unveil Florbetaben Data at CTAD 2025 Could Diagnostic Innovation Strengthen Its Edge?

Lantheus Holdings announced it will present new florbetaben F18 data at the Clinical Trials on Alzheimer’s Disease (CTAD) 2025 conference in San Diego, with the...

Lantheus Holdings To Unveil Florbetaben Data at CTAD 2025 Could Diagnostic Innovation Strengthen Its Edge?

Analyst ratings

77%

of 13 ratings
Buy
76.9%
Hold
23.1%
Sell
0%

People also own

Based on the portfolios of people who own LNTH. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.